Clinical Trials Browser

Phase 3 × olaparib × 30 days × Clear all

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04421963 2026-04-16

ROSY-O

Phase 3 Active not recruiting

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT03486873 2026-04-13

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT06915025 2026-04-13

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT07486687 2026-03-20

PLANET

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms